In one paragraphTrial report in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Nahir Rodríguez-CostasMicrobiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), 36312 Vigo, Spain.ORCID 0009-0005-5670-1898 Cristina Regueiro ExpósitoResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.ORCID 0000-0002-8567-6784 Joaquín CubiellaResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.ORCID 0000-0002-9994-4831 Esteban Sinde StompelHifas da Terra S.L., 36154 Pontevedra, Spain.
Astrid Irene Diez MartínResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.ORCID 0000-0001-8822-2991 Pablo Taboada-RodríguezEscuela Técnica Superior de Ingeniería (ETSE), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0009-0005-0139-9951 Belén Fontán SilvaMicrobiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), 36312 Vigo, Spain.
María Dolores Rodríguez FernándezMicrobiology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), 36312 Vigo, Spain.
Sara ZarraquiñosDepartment of Gastroenterology, Hospital Universitario de Ourense, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 32005 Ourense, Spain.
David RemediosDepartment of Gastroenterology, Hospital Universitario de Ourense, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 32005 Ourense, Spain.ORCID 0000-0003-2682-0317 Cristina Alejandra Sánchez GómezDepartment of Gastroenterology, Hospital Universitario de Ourense, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 32005 Ourense, Spain.ORCID 0000-0003-0924-2295 Sara Alonso LorenzoResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.
Romina Fernández PoceiroResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.
María Luisa de Castro PargaResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.ORCID 0000-0001-7848-7910 Vicent Hernández RamírezResearch Group in Gastrointestinal Oncology Disease in Ourense, 32005 Ourense, Spain.ORCID 0000-0003-1607-0831 Sonia Pérez-CastroMicrobiology and Infectology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), 36312 Vigo, Spain.ORCID 0000-0003-1734-1904 Funding
Centre for Industrial Technological Development N.º Solicitud SOL-00105490, N.º Expediente EXP0010549
6 · The paper itselfAbstract
The gut microbiome is increasingly recognized as an important determinant of host immune regulation, intestinal homeostasis, and recovery after colorectal cancer (CRC) surgery. Although our previous randomized, double-blind, placebo-controlled clinical trial demonstrated that fungal nutraceutical supplementation with Micodigest
Indexed as
Colorectal NeoplasmsDietary SupplementsFungiGastrointestinal MicrobiomeAgedFecesFemaleHumansMaleMetagenomicsMiddle Agedcolorectal cancerfunctional metagenomicsfungal nutraceuticalsgut microbiomeinflammation
Identifiers
PMID42884177
PMCPMC13665136
What OpenQuestion holds
Textmetadata
Read underepoch 390